Merck + Co., Inc.

Prakash S Masurekar

Louis Kaplan

David F Sesin

Jimmy M Fountoulakis

Jerrold M Liesch

Otto D Hensens

Robert E Schwartz

Carol F Wichmann

Thomas C Hallada

Margaret S Sosa

Deborah L Zink

Richard L Monaghan

Robert A Giacobbe

Claude Dufresne

Rosemarie Kelly

Jan S Tkacz

Elizabeth A Register

Wesley L Shoop

Leslie A Ferrell

Michael A Wallace

There is disclosed an isolated gene coding for an enzyme involved in proline biosynthesis in Zalerion arboricola. There is also disclosed a method of using the gene to produce a strain of Z. arboricola containing high titers of a desirable fermentation product.

P5C reductase gene from zalerion arboricloa

An active avermectin analogue which can be produced by directed biosynthesis is described. The compound, named 26-R-Avermectin B.sub.1 a, is active in the Haemonchus egg to L3 assay and has the following structure: ##STR1##

Active avermectin analogue

A process for producing an antibiotic compound which is normally a minor component in the cultivation of Z. arboricola to be the major product is described.

Process for production of an antibiotic compound with Zalerion arboricola

A new antibiotic cyclic lipopeptide having the formula ##STR1## wherein R is H or OH and a method of producing is described. The agent has very high activity against human pathogens and is of very low mammalian toxicity.

Antibiotic agent

New Zaragozic acids have been isolated from a culture of MF5465. These compounds and their derivatives are active as squalene synthetase inhibitors and are useful in the treatment of hypercholesterolemia.

Cholesterol lowering compounds

A new antibiotic cyclic lipopeptide having the formula ##STR1## wherein R is H SEQ ID NO:1 or OH SEQ ID NO:2 and a method of producing is described. The agent has very high activity against human pathogens and is of very low mammalian toxicity.

A new antibiotic cyclic lipopeptide and a method of producing it are described. The agent has very high activity against human pathogens and is of very low mammalian toxicity.

Process for producing a cyclic lipopeptide employing zalerion arboricola

A process for producing an antibiotic compound which is normally one of several minor components in the cultivation of Z. arboricola ATCC 20868 to be the primary product is described.

Process for production of an antibiotic compound using Zalerion

Antibiotic agents

An antibiotic agent produced by the cultivation of Zalerion arboricola which is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity and its production and isolation are described.

Growing community of inventors

Warren, NJ, United States of America

Prakash S Masurekar